Sexual well-being in people treated for gynecologic cancer and their partners
Official title: Assessment of Sexual Well-being in Patients With Gynecologic Cancer and Their Partners: the ONCOSEX Study
Run by Casa di Cura Dott. Pederzoli · NCT07557342 · Data updated 2026-11-12
This project will follow people with gynecologic cancer and their partners to see if their sexual function changes over time using questionnaires and brief exams.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Casa di Cura Dott. Pederzoli Academic / other |
| Locations | 6 sites (Bologna, Bologna and 5 other locations) |
| Status | Recruiting |
| Main results expected | October 2026 |
| Study ends | April 2028 |
| Registry record updated | October 22, 2026 |
| Trial ID | NCT07557342 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Sexually active women aged 18–75 diagnosed with a malignant gynecologic tumor who have a partner, can speak Italian, and are willing to have their partner enroll and sign consent.
✕Probably not a fit
Women who are not sexually active, are under 18 or over 75, have benign gynecologic conditions, or who already received sexual counseling are unlikely to benefit from the observational findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, longitudinal, multicenter observational cohort that follows sexually active patients with gynecologic cancers and their partners without changing standard clinical care. Participants complete validated sexual function questionnaires and undergo brief physical exams at multiple time points to document changes over time. The study is exploratory and non‑profit, aiming to include several Italian centers to capture a diverse patient population. Data collection focuses on patient- and partner-reported outcomes to better characterize couple dynamics and sexual quality of life after cancer.
Why it matters
Potential benefit: If successful, the findings could clarify common patterns of sexual dysfunction after gynecologic cancer and inform the design of targeted counseling and support pathways.
How similar studies have gone: Previous observational work has documented declines in sexual quality of life after gynecologic cancer, but few multicenter longitudinal cohorts that include partners and inform structured counseling pathways have been published.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with gynecological cancer: malignant ovarian tumor, ovarian tumor of uncertain behavior, cervical cancer, endometrial cancer, uterine sarcoma, vulvar cancer, vaginal cancer * Sexually active * Women who have a partner * Aged between 18 and 75 * Women of any sexual orientation * Understanding and knowledge of the Italian language * Signing of the informed consent form * Signing of the informed consent form by the partner Exclusion Criteria: * Benign gynecological conditions * Age \< 18 or \> 75 * Virgins or women who are no longer sexually active * Women with psychiatric or neurological disorders * Women or partners who have already undergone sexual counseling or sex therapy * Women who are unable to sign the informed consent form for the study
Where it's running
-
Ospedale P. Pederzoli Casa di Cura Privata S.p.A.
Peschiera del Garda, Verona, Italy Recruiting -
IRCCS Azienda ospedaliero-universitaria di Bologna - Policlinico Sant'Orsola
Bologna, Bologna, Italy Not yet recruiting -
IEO - Istituto Europeo di Oncologia
Padova, Padova, Italy Not yet recruiting -
Policlinico Universitario Fondazione Agostino Gemelli
Roma, Roma, Italy Not yet recruiting -
IRCCS Materno infantile Burlo Garofolo
Trieste, Trieste, Italy Not yet recruiting -
Presidio Ospedaliero Universitario "Santa Maria della Misericordia"
Udine, Udine, Italy Not yet recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Immunonutrition and Brain Monitoring to See if Delirium Happens After Gynecologic Cancer Surgery
This study tests whether a preoperative immunonutrition scoring plus intraoperative brain monitoring can help predict or relate to postoperative delirium in women aged 65 and older undergoing major gynecologic cancer surgery.
-
Prophylactic subcutaneous drainage after gynecologic cancer surgery
This study tests whether placing a small drain under the skin after gynecologic cancer surgery helps prevent wound problems in women with thicker tissue under the skin.
-
Feasibility of high-dose multimodal prehabilitation for women awaiting gynecologic cancer surgery
This study tests whether a high-dose, multimodal prehabilitation program can be delivered before gynecologic cancer surgery and whether patients prefer in-person, remote, or education-only approaches.
-
Romiplostim N01 plus ATRA for persistent chemotherapy-induced low platelets after remission from gynecologic, breast, or lung cancer
This trial tests whether adding ATRA to Romiplostim N01 helps people keep a safe platelet count after finishing chemotherapy for certain cancers.
-
Shatavari root extract for women's sexual wellness
This trial will test whether taking a daily Shatavari root supplement for 12 weeks helps women aged 20–50 with low sexual function and high perceived stress improve sexual wellness.
-
Personalized diet to help women with advanced gynecologic or breast cancer on ADC therapy
This study tests a personalized dietary plan versus general Mediterranean diet guidance in women with advanced gynecologic or breast cancer who are being treated with antibody-drug conjugates to see if nutrition can improve quality of life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.